drugset
drugset / Trial / NCT05613842

Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)

NCT05613842 ↗

Phase 2 Completed 30 enrolled St Vincent's Hospital, Sydney Clarity Pharmaceuticals Ltd · collab
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This phase 2a study will involve enrolment of men presenting with progression of biopsy proven prostate cancer who require imaging for staging/re-staging of their disease. The participants enrolled will be further sub-stratified into two groups; one group of men with hormone-sensitive disease (cohort A), and a second group of men with castrate-resistant disease being considered for 177Lu-PSMA-617 therapy (Cohort B).

Timeline

Start
2022-08-09
Primary completion
2023-06-06
Completion
2023-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject 64Cu-SAR-BBN Diagnostic / imaging agent 200 mbq —

Indications

prostate cancer